Extracellular Matrix (ECM) Therapy in Rochester, NY

CDC PLACES vs. JK: two files, not one brochure

Joe Bradley will tell you the same thing he tells his own staff: epidemiology first, then MAC, then SKU. CDC PLACES (2023, crude) estimates 14.3% of adults in Rochester have diagnosed diabetes — 2.3 points above the U.S. 12% figure. 10.9% of adults 18–64 here currently lack health insurance (CDC PLACES ACCESS2, 2023). Cash-pay PRP and Medicare CTPs cannot share one consent script. Then we pick extracellular matrix therapy against that mix.

Where Rochester programs actually stall

• CDC PLACES (2023, crude) estimates 14.3% of adults in Rochester have diagnosed diabetes — 2.3 points above the U.S. 12% figure. Adult arthritis here is 24.9% (CDC PLACES 2023, crude). That is the joint-pain backdrop for PRP and orthobiologics — not a promise that every arthritic knee is a candidate. Separate 361 tissue, PRP, and CTP tickets before you market extracellular matrix therapy in Rochester. Mixing lanes is how recoupments start.
• New York is outside CDC's historical Diabetes Belt core, but the national 12% diabetes figure still applies as a planning baseline until a clinic uses its own payer mix. Clinics asking for regenerative inventory still have to separate HCT/P 361 homologous-use products from unapproved “stem cell” claims (FDA 21 CFR 1271).
• HCT/P 361 products must be minimally manipulated and used homologously. New York medical boards and the FTC have both acted against regenerative advertising that implies stem-cell cures. Inventory choice and website copy have to match.

Uninsured mix and Medicare CTPs in the same building

JK reviewers still want serial wound measurements and conservative-care history before CTPs, whether diabetes in Rochester is 14.3% or not. PLACES is planning data. The LCD is the claim.

Staff, tickets, photos — in that order